The role of modern SUs in the T2DM continuum: newly diagnosed, uncontrolled or high HbA1c, obese/overweight, with CVD/HF, with CKD, elderly/high risk of hypoglycemia or long-standing T2DM or on insulin.

All 4 gliptin trials showed CV safety but no CV benefits.

Severe hypoglycemia and weight gain were negligible with the gliclazide-based strategy.

Sulfonylureas lower blood glucose. Giving too much is a problem, so we need to be cautious and careful in dosing.

HbA1c reduction with SUs are the best among OADs and next only to insulin.